Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (465)	12/19/1997 11:03:00 AM
From: Robert Voigt	Read Replies (1) \| Respond to of 965

Danke

To: FNS who wrote (465)	12/19/1997 6:10:00 PM
From: Robert Voigt	Read Replies (4) \| Respond to of 965

Yesterday, in "TheStreet.com" James Cramer discussed possible side effects of Avakine. He said that 5 patients out of 63 suffered seious side effects vs no sidefeects in the placebo group of 31 patients. He also stated that the FDA hasn't seen this data yet. He says that the company says there are no significant differences in the results, but short sellers are saying this is potentially very damaging. He quotes Rachel Leheny, of Hambrecht & Quist as saying "The best indication we'll have [that Avakine is safe] is if the FDA gives it accelerated review." Hopefully that will happen (accelerated review). Anyone else have anything on this subject?